logo

HSCS

HeartSciences
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 3
consensus rating "Strong Buy"
ample liquidity
Net Income Plunges
EPS Below Expectations
Revenue Keeps Dropping

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About HSCS

Heartsciences Inc.

A medical technology company that provides solutions to understand heart disease

Healthcare Equipment and Supplies
Invalid Date
06/15/2022
NASDAQ Stock Exchange
15
04-30
Common stock
550 Reserve St, Suite 360, Southlake, Texas 76092
--
HeartSciences Inc., was incorporated in Texas in August 2007. They are a medical technology company focused on applying innovative artificial intelligence-based technologies to electrocardiograms to expand and improve the clinical usefulness of electrocardiograms. Their goal is to make ECG a more valuable cardiac screening tool, especially in front-line or bedside clinical settings. HeartSciences' first FDA-approved product candidate, MyoVistawavECG, is a resting 12-lead electrocardiogram that is also designed to provide diagnostic information related to cardiac dysfunction traditionally only available through the use of cardiac imaging.

Company Financials

EPS

HSCS has released its 2025 Q2 earnings. EPS was reported at -2.27, versus the expected -2.34, beating expectations. The chart below visualizes how HSCS has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime